Oricell Therapeutics secured a pre-IPO venture financing worth more than $110 million to advance CAR-T programs aimed at solid tumors. The company’s lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T program being developed for advanced hepatocellular carcinoma. Oricell said Ori-C101 has completed early human testing across three dose levels in a 10-patient study, reporting an objective response at the highest dose and a disease-control signal. The funding is also intended to support a broader set of next-generation cell-therapy modalities, including additional CAR-T programs and in vivo approaches. The financing arrives as the company positions for capital-market milestones and expands a strategy tailored to the antigen heterogeneity and immunosuppressive microenvironments that complicate solid-tumor cell therapy.